| Name | Title | Contact Details |
|---|
Advanced Health Education Center is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Homeward is rearchitecting rural health and care for the 60 million Americans living in rural communities. Homeward employs a multidisciplinary care team, available both virtually and on the ground via mobile care units, with in-home remote monitoring to better connect patients to high-quality, affordable and comprehensive care. Today, the company partners with Medicare Advantage plans, taking on the full risk of their members to improve outcomes and reduce costs.
ChemoCentryx Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Mountain View, CA. To find more information about ChemoCentryx Inc, please visit www.chemocentryx.com
St Vincent Infirmary Medical Center is a Little Rock, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.